undamentalytics Newsletter
Sign in

Sensus Healthcare, Inc. (SRTS) stock

Add to watchlist

Add holding +

NASDAQ: SRTS Nasdaq Health Care Equipment Next results ~November 12, 2026

C Fundamentals grade

Sensus Healthcare, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.9

Valuation models combined (5)

Base case. Range ~$0.8–$3.0. Weighted average of 5 models (growth cash-flow model, residual income, justified price-to-book, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Sensus Healthcare, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 0 selling21 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds12 adding, 17 cuttingOf 3 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Sensus Healthcare files

Where Sensus Healthcare stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $18m, down 53.4% on a year earlier, a steeper fall than the 42.9% decline a quarter earlier. That puts it 101 of 103 for growth among the health care equipment companies we cover. Free-cash-flow margin fell to -39.8% from 9.3% a year earlier. Operating margin narrowed to -75.7% from -3.6%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Sensus Healthcare, Inc.'s trailing-twelve-month revenue fell 53.4% year on year, with a free-cash-flow margin of -39.8%. Where it stands out: days sales outstanding of 35 days ranks 13 of 118 health care equipment companies we cover. Where it lags: revenue growth of -53.4% ranks 127 of 129 health care equipment companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -53.4% (-10.5pp vs the prior quarter), the 6th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 53.4% over the last 12 months.
  • Growth slowing. The growth rate is 10.5 points lower than a quarter earlier.
  • Loss-making. Operating margin is -75.7%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 72.1 points on a year ago.
  • Burning cash. Free cash flow was -39.8% of revenue over the last 12 months.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$0.53 against an average estimate of -$0.11: missed by 381.8%
Revenue
$2m, down 68.7% on a year earlier
Share reaction
-8.6% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.04

Sensus Healthcare's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.4%
  • 1 week-2.5%
  • 1 month-7.7%
  • This year-30.9%
  • 1 year-13.8%
  • 5 years-31.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$17.5M
Operating margin
-75.7%
Net margin
-88.5%
EPS (TTM, diluted)
$-0.94

Growth

Revenue growth
−53.4%
Change in growth rate
−10.5 pts
Share count change
+0.2%

Cash

Free cash flow (TTM)
-$7M
FCF margin
-39.8%
Stock pay % of revenue
1.2%

Earnings

Last results
August 13, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Sensus Healthcare, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Sensus Healthcare, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.02 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.1 ~$0.2–$2.0 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$3.0 ~$2.0–$4.6 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$3.0 ~$2.6–$3.6 Included
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.1 ~$2.3–$8.0 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.8 ~$0.8–$0.9 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.9 ~$0.8–$3.0 5 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Sensus Healthcare, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$5.25$5.16$7.41$3.54$3.86$7.22$7.42$2.36$6.92$3.98$2.75
Market value$63m$68m$105m$57m$63m$119m$123m$38m$113m$65m$45m
+ Net debt (− = net cash)−$5m−$8m−$12m−$8m−$15m−$15m−$26m−$23m−$22m−$22m−$15m
Enterprise value$58m$60m$92m$49m$49m$105m$98m$15m$91m$43m$30m
Multiples
Price / sales 4.3x3.3x4.0x2.1x6.6x4.4x2.8x1.6x2.7x2.4x2.6x
Price / earnings —————28.9x5.1x79.2x17.0x——
Price / free cash flow —————————195.7x—
EV / EBITDA —————22.1x6.5x—11.0x——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

43 /100

Weak moat

How hard Sensus Healthcare's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -7.2% of total assets over 10 years.

  • Pricing power 13 / 20

    Gross margin has been a median 61.7%, moving by 8.8 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -11.0%; its worst year was -75.7%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 3 of 10 years, at a median -20.0% of revenue.

  • Discipline 17 / 20

    The diluted share count fell 0.4% over five years; stock-based pay has been a median 1.3% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $7m and EPS of −$0.04 (range −$0.08 to $0.02) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.76 −62% $19m −30%
Next −$0.17 +77% $28m +47%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +159.1% on 90 days ago. In the last 30 days, 0 analysts raised Sensus Healthcare, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Sensus Healthcare, Inc., last 90 days
−$0.80 −$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.29 Current fiscal year, 60 days ago: −$0.29 Current fiscal year, 30 days ago: −$0.33 Current fiscal year, 7 days ago: −$0.33 Current fiscal year, Now: −$0.76 −$0.76 Next fiscal year, 90 days ago: −$0.02 Next fiscal year, 60 days ago: −$0.02 Next fiscal year, 30 days ago: −$0.09 Next fiscal year, 7 days ago: −$0.09 Next fiscal year, Now: −$0.17 −$0.17

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.29−$0.02
60 days ago −$0.29−$0.02
30 days ago −$0.33−$0.09
7 days ago −$0.33−$0.09
Now −$0.76−$0.17

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.11 −$0.53 −381.8%
Mar 2026 −$0.11 −$0.16 −45.5%
Dec 2025 −$0.06 −$0.19 −245.4%
Sept 2025 −$0.11 −$0.06 +45.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026134
  2. Sep 2026134

Counts of recommendations published by analysts covering Sensus Healthcare, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.6%
of tradable shares
Days to cover
10.18
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
28%
of shares
Held by insiders
18.7%
of shares
Employees
60
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −13.8%

$3.19 on October 31, 2025 to $2.75

ThenNowEffect
Revenue (last 12 months) $38m $18m −53.4%
P/S multiple 1.4x 2.6x +85.3%
Share count 16m 16m −0.2%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +25.0%

$2.20 on November 3, 2023 to $2.75

ThenNowEffect
Revenue (last 12 months) $30m $18m −41.8%
P/S multiple 1.2x 2.6x +114.2%
Share count 16m 16m +0.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
SRTS+87%+3%−68%+193%−43%−31%
Industry peers (median)−9%−37%−8%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SRTS58%67%33%58%42%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SRTS−36%−61%−80%−36%−66%−49%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since July 26, 2016: 88% from August 12, 2022 to November 13, 2023. Getting back needed a 701% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.69 – $5.30
From 52-week high
−48.1%
vs 50-day average
−9.2%
vs 200-day average
−22.0%
Volatility (1 year)
64%
Beta vs S&P 500
0.85

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±17.5%
After a week
7 up, 5 down
typical move ±21.3%
After a month
3 up, 9 down
typical move ±17.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −8.6% +0.5% +3.2% 0.0%
May 7, 2026 −24.7% +0.5% −11.7% −34.2%
February 12, 2026 −18.9% −1.5% −17.0% −16.8%
November 6, 2025 +13.8% −1.0% +20.9% +2.2%
August 7, 2025 −35.0% +0.7% −35.5% −39.4%
May 15, 2025 −7.5% +1.1% −2.9% 0.0%
February 5, 2025 −28.0% +0.8% −33.1% −45.5%
November 18, 2024 +9.5% +0.8% +14.9% −3.1%
November 14, 2024 +11.0% −1.9% +29.8% +15.8%
August 8, 2024 +7.9% +2.8% +7.9% −2.0%
May 9, 2024 +38.1% +0.7% +67.6% +43.1%
February 8, 2024 +6.6% +0.6% +11.3% −6.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Sensus Healthcare, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Sensus Healthcare, Inc.
$10M $20M $30M $40M $50M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $24.9M Revenue (TTM), FY23 Q4: $24.4M Revenue (TTM), FY24 Q1: $31.7M Revenue (TTM), FY24 Q2: $36.4M Revenue (TTM), FY24 Q3: $41.3M Revenue (TTM), FY24 Q4: $41.8M Revenue (TTM), FY25 Q1: $39.5M Revenue (TTM), FY25 Q2: $37.6M Revenue (TTM), FY25 Q3: $35.6M Revenue (TTM), FY25 Q4: $27.5M Revenue (TTM), FY26 Q1: $22.5M Revenue (TTM), FY26 Q2: $17.5M $17.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $24.9M
FY23 Q4 $24.4M
FY24 Q1 $31.7M
FY24 Q2 $36.4M
FY24 Q3 $41.3M
FY24 Q4 $41.8M
FY25 Q1 $39.5M
FY25 Q2 $37.6M
FY25 Q3 $35.6M
FY25 Q4 $27.5M
FY26 Q1 $22.5M
FY26 Q2 $17.5M
Revenue growth, TTM YoY Sensus Healthcare, Inc.
-100% -50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -43.9% Revenue growth, TTM YoY, FY23 Q4: -45.2% Revenue growth, TTM YoY, FY24 Q1: -15.8% Revenue growth, TTM YoY, FY24 Q2: 21.0% Revenue growth, TTM YoY, FY24 Q3: 65.6% Revenue growth, TTM YoY, FY24 Q4: 71.3% Revenue growth, TTM YoY, FY25 Q1: 24.7% Revenue growth, TTM YoY, FY25 Q2: 3.3% Revenue growth, TTM YoY, FY25 Q3: -13.8% Revenue growth, TTM YoY, FY25 Q4: -34.3% Revenue growth, TTM YoY, FY26 Q1: -42.9% Revenue growth, TTM YoY, FY26 Q2: -53.4% -53.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -43.9%
FY23 Q4 -45.2%
FY24 Q1 -15.8%
FY24 Q2 21.0%
FY24 Q3 65.6%
FY24 Q4 71.3%
FY25 Q1 24.7%
FY25 Q2 3.3%
FY25 Q3 -13.8%
FY25 Q4 -34.3%
FY26 Q1 -42.9%
FY26 Q2 -53.4%
Operating margin (TTM) Sensus Healthcare, Inc.
-100% -50% 0% 50% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -7.2% Operating margin (TTM), FY23 Q4: -1.6% Operating margin (TTM), FY24 Q1: 17.2% Operating margin (TTM), FY24 Q2: 23.5% Operating margin (TTM), FY24 Q3: 28.9% Operating margin (TTM), FY24 Q4: 19.4% Operating margin (TTM), FY25 Q1: 6.5% Operating margin (TTM), FY25 Q2: -3.6% Operating margin (TTM), FY25 Q3: -15.3% Operating margin (TTM), FY25 Q4: -37.5% Operating margin (TTM), FY26 Q1: -53.3% Operating margin (TTM), FY26 Q2: -75.7% -75.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -7.2%
FY23 Q4 -1.6%
FY24 Q1 17.2%
FY24 Q2 23.5%
FY24 Q3 28.9%
FY24 Q4 19.4%
FY25 Q1 6.5%
FY25 Q2 -3.6%
FY25 Q3 -15.3%
FY25 Q4 -37.5%
FY26 Q1 -53.3%
FY26 Q2 -75.7%
FCF margin (TTM) Sensus Healthcare, Inc.
-80% -60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -60.8% FCF margin (TTM), FY23 Q4: -9.7% FCF margin (TTM), FY24 Q1: -14.6% FCF margin (TTM), FY24 Q2: -3.0% FCF margin (TTM), FY24 Q3: 5.1% FCF margin (TTM), FY24 Q4: -2.6% FCF margin (TTM), FY25 Q1: 11.7% FCF margin (TTM), FY25 Q2: 9.3% FCF margin (TTM), FY25 Q3: 6.1% FCF margin (TTM), FY25 Q4: 1.2% FCF margin (TTM), FY26 Q1: -3.3% FCF margin (TTM), FY26 Q2: -39.8% -39.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -60.8%
FY23 Q4 -9.7%
FY24 Q1 -14.6%
FY24 Q2 -3.0%
FY24 Q3 5.1%
FY24 Q4 -2.6%
FY25 Q1 11.7%
FY25 Q2 9.3%
FY25 Q3 6.1%
FY25 Q4 1.2%
FY26 Q1 -3.3%
FY26 Q2 -39.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 10 15 21 26 27 10 27 45 24 42 27 18
Gross profit 7 10 14 17 18 5 17 30 14 24 12 6
EBITDA 0 −0 −3 −1 −1 −8 5 15 −0 8 −10 −13
Operating income −0 −0 −4 −2 −2 −8 4 15 −0 8 −10 −13
Net income −0 −0 −4 −2 −2 −7 4 24 0 7 −8 −15
Diluted EPS −$0.08 −$0.03 −$0.28 −$0.14 −$0.10 −$0.42 $0.25 $1.46 $0.03 $0.41 −$0.47 −$0.94
Growth (year on year)
Revenue — +44.2% +39.0% +28.4% +3.2% −64.9% +182.4% +64.7% −45.2% +71.3% −34.3% −53.4%
EBITDA — — — — — — — +220.0% −100.7% — −219.5% —
Operating income — — — — — — — +260.0% −102.6% — −227.4% —
Net income — — — — — — — +488.6% −98.0% — −216.1% —
Diluted EPS — — — — — — — +484.0% −97.9% — −214.6% —
Margins
Gross margin 64.1% 66.5% 67.0% 64.0% 64.4% 54.8% 62.8% 66.5% 57.6% 58.4% 43.2% 36.4%
EBITDA margin 0.9% −0.2% −16.2% −5.1% −5.2% −78.4% 17.5% 34.0% −0.4% 19.8% −36.0% −73.4%
Operating margin −2.2% −2.5% −18.1% −7.6% −7.2% −86.0% 15.2% 33.3% −1.6% 19.4% −37.5% −75.7%
Net margin −2.3% −2.3% −18.0% −7.7% −6.2% −71.4% 15.2% 54.4% 2.0% 15.9% −28.1% −88.5%
Free-cash-flow margin −14.9% −7.7% −16.2% −35.6% −9.2% −8.3% −1.5% −3.5% −9.7% −2.6% 1.2% −39.8%
Cash flow
Cash from operations −1 −1 −3 −9 −2 −0 −0 −1 −2 −1 1 −7
Capital spending 0 0 0 1 0 0 0 0 0 0 0 0
Free cash flow −2 −1 −3 −9 −3 −1 −0 −2 −2 −1 0 −7
Stock-based pay 0 1 0 1 1 0 0 0 0 0 0 0
Free cash flow after stock pay −2 −2 −4 −10 −3 −1 −1 −2 −3 −1 0 −7
Balance sheet
Cash 5 5 10 12 8 15 15 26 23 22 22 15
Total debt 0 0 2 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −5 −5 −8 −12 −8 −15 −15 −26 −23 −22 −22 −15
Diluted shares 10m 12m 13m 14m 16m 16m 17m 17m 16m 16m 16m 16m
Returned to shareholders
Buybacks — — — — — — — 3 0 — 0 —
Total returned — — — — — — — 3 0 — 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $41m
Short-term assets $38mLonger-term assets $4m
What it owes, and who funded it · $41m
Short-term liabilities $4mLonger-term liabilities $0mShareholders' equity $37m
  • Short-term assets cover short-term liabilities $38m of assets due within a year against $4m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $38m short-term assets against $69,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Sensus Healthcare, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$300,000
Returned to shareholders
90%
of free cash flow
Buybacks, last 3 fiscal years
$3.3M
Diluted share count
+0.2%
year over year
Total shareholder yield
0.7%
dividends 0.0% + buybacks 0.7% of market value
R&D spending
36.6%
of revenue
Sales & admin spending
42.9%
of revenue
Days sales outstanding
35 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated SRTS HYPR MDAI ZJYL NEPH VVOS Median
Revenue, last 12 months $18m $17m $15m $21m $21m $21m $99m
Revenue growth, last 12 months −53.4% 53.2% −44.1% −12.0% 24.2% 45.2% 9.2%
Revenue growth, 3-year average −16.5% 19.1% −11.8% — 19.3% 10.6% 13.5%
Revenue growth, latest quarter −68.7% 44.8% −30.4% — 36.2% 34.9% 10.2%
Gross margin 36.4% 51.4% 42.9% 29.2% 61.3% 61.9% 61.2%
Operating margin −75.7% −203.3% −77.2% 2.9% 7.9% −107.9% −8.5%
Operating margin, 3-year average −18.6% −323.4% −49.1% — 2.0% −101.0% −17.9%
Net margin −88.5% −210.8% −65.5% 5.8% 8.4% −121.8% −12.0%
Cash from operations / revenue −38.8% −163.7% −83.7% 14.0% −3.4% −82.0% −1.9%
Free-cash-flow margin −39.8% −166.5% −84.4% −18.0% −4.0% −91.0% −3.9%
Free-cash-flow margin, 3-year average −11.2% −279.4% −58.8% — −0.1% −94.3% −7.0%
Stock pay / revenue 1.2% 17.3% 10.0% — 1.3% 1.9% 6.1%
Change in share count 0.2% 23.9% 38.4% 0.0% 4.0% 20.4% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -53.4% 9.1% 127 of 129
Change in growth rate Growth -10.5pp -0.6pp 110 of 129
Gross margin Profitability 36.4% 61.9% 101 of 123
Operating margin Profitability -75.7% -8.3% 98 of 132
Net margin Profitability -88.5% -12.0% 102 of 133
Free-cash-flow margin Cash generation -39.8% -3.4% 92 of 128
Stock pay as % of revenue Cash generation 1.2% 6.1% 15 of 123
Change in share count Balance sheet 0.2% 3.3% 35 of 115
Days sales outstanding Balance sheet 35 days 57 days 13 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $19.8M 71.9% ▼ 45.7%
Service Revenue $3.5M 12.6% ▲ 8.1%
Services $2.5M 9.2% ▲ 29.6%
Product Revenue $1.7M 6.3% ▲ 596.8%
Geography
Region Revenue Share YoY
United States $25.4M 92.3% ▼ 36.9%
China $2M 7.4% ▲ 40.5%
Other $90,000 0.3% ▼ 50.5%

From Sensus Healthcare, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$11M
Institutions reporting
38
Shares held vs prior quarter
▼ 7.6%
Positions opened / closed
4 / 5

Top buyers and sellers, Q2 2026: 12 institutions bought and 17 sold ; the biggest buyer was Ep Wealth Advisors, LLC (+16K shares) and the biggest seller Meros Investment Management, LP (−152K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Pacific Ridge Capital Partners, LLC $2.4M 790K 21.6% ▼ 0.8%
Vanguard Capital Management LLC $2M 660K 18.1% ▲ 1.9%
Dimensional Fund Advisors LP $954,758 316K 8.7% ▼ 18.4%
Divisadero Street Capital Management, LP $841,025 278K 7.6% ▼ 2.7%
Renaissance Technologies LLC $731,849 242K 6.6% ▼ 3.9%
Geode Capital Management, LLC $465,656 154K 4.2% ▼ 6.9%
UBS Group AG $460,770 153K 4.2% ▼ 11.7%
Sachetta, LLC $459,066 152K 4.2% ▲ 1.0%
Greenline Wealth Management LLC $388,897 129K 3.5% 0.0%
North Star Investment Management Corp. $379,270 126K 3.4% 0.0%
Bank Of New York Mellon Corp $303,239 100K 2.8% 0.0%
Blackrock, Inc. $252,336 84K 2.3% ▲ 17.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Sensus Healthcare, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $740,769 21 trades by 3 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $740,769 net buying
Insider Date Trade Shares Price Value
Sachetta Eric Director August 31, 2026 Buy 27,304 $3.54 $96,656
Sachetta Eric Director August 28, 2026 Buy 37,537 $3.44 $129,127
Sachetta Eric Director August 27, 2026 Buy 10,925 $3.18 $34,742
Sachetta Eric Director August 26, 2026 Buy 9,708 $3.29 $31,939
Sachetta Eric Director August 24, 2026 Buy 34,697 $3.25 $112,765
Sachetta Eric Director August 21, 2026 Buy 7,000 $3.25 $22,750
Sachetta Eric Director August 20, 2026 Buy 24,000 $3.13 $75,120
Sardano Joseph C CHIEF EXECUTIVE OFFICER August 20, 2026 Buy 20,000 $3.02 $60,400
Sachetta Eric Director May 12, 2026 Buy 1,500 $3.34 $5,010
Sachetta Eric Director February 24, 2026 Buy 2,000 $3.81 $7,620
Sachetta Eric Director November 21, 2025 Buy 7,000 $3.93 $27,510
Sardano Michael PRESIDENT AND GENERAL COUNSEL November 18, 2025 Buy 1,000 $3.80 $3,800

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 7, 2026
  • February 12, 2026
  • November 6, 2025
  • August 7, 2025
  • May 15, 2025

Recent SEC filings

Data status

When each part of this page on Sensus Healthcare, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Sensus Healthcare, Inc. in brief

What does Sensus Healthcare, Inc. do?
Sensus Healthcare, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Sensus Healthcare, Inc.'s stock ticker?
Sensus Healthcare, Inc. trades under the ticker SRTS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Sensus Healthcare, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Sensus Healthcare, Inc. reported revenue of $17.5M, 53.4% lower than a year earlier, according to its SEC filings.
What is Sensus Healthcare, Inc.'s free cash flow?
Sensus Healthcare, Inc.'s free-cash-flow margin is -39.8% of revenue over the trailing twelve months, ranking 92 of the 128 health care equipment companies we cover.
Who are Sensus Healthcare, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Pacific Ridge Capital Partners, LLC, Vanguard Capital Management LLC and Dimensional Fund Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Sensus Healthcare, Inc. buying back stock, and does it pay a dividend?
Sensus Healthcare, Inc. spent $300,000 on share repurchases over the trailing twelve months, and its diluted share count still rose 0.2% over the year.
What is Sensus Healthcare, Inc.'s market cap?
On November 2, 2026, Sensus Healthcare, Inc.'s market capitalisation was about $45.1M and net debt of -$15.2M. Market figures come from third-party market data and may be delayed.
Who are Sensus Healthcare, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Sensus Healthcare, Inc. are Hyperfine, Inc., Spectral AI, Inc., Jin Medical International Ltd., Nephros Inc and Vivos Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Sensus Healthcare, Inc.'s.
Are insiders buying or selling Sensus Healthcare, Inc. stock?
Over the last 12 months, Sensus Healthcare, Inc.'s directors and officers reported 21 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Sensus Healthcare, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Sensus Healthcare, Inc. announces its own schedule.